Associated Papers
EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors.
Liu Y et al.
Journal of Thoracic Disease, 2022
Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer.
Wei B et al.
Pathology, Research and Practice, 2017
Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.
Shan L et al.
Lung Cancer (amsterdam, Netherlands), 2015
Select a paper to view details